Difference between revisions of "Part:BBa K4375006"
Zsoka csorba (Talk | contribs) (→References) |
|||
| (3 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
<partinfo>BBa_K4375006 short</partinfo> | <partinfo>BBa_K4375006 short</partinfo> | ||
| − | |||
CEA-specific (carcinoembryonic antigen) Nanobody is optimized for production in E. coli. This Nanobody has the ability to bind to the CEA antigen and thus can be used to identify cells over expressing the CEA antigen, which is common in various cancers. | CEA-specific (carcinoembryonic antigen) Nanobody is optimized for production in E. coli. This Nanobody has the ability to bind to the CEA antigen and thus can be used to identify cells over expressing the CEA antigen, which is common in various cancers. | ||
| − | |||
<html> | <html> | ||
| Line 14: | Line 12: | ||
==Usage and Biology== | ==Usage and Biology== | ||
| − | |||
| − | |||
Nanobodies are monomeric, single-domain antibody fragments derived from camelids and are useful in therapies due to their small size and specific antigen binding. Nanobodies can be expressed in bacterial systems because unlike antibodies, it has no characteristic post-translational modification like glycosylation. Fused to a cargo they can easily penetrate solid tumors and have the desired effect like killing cells locally. Anti-CEA nanobody is targeting the immunglobulin-like glycoprotein CEA (carcinoembryonic antigen) which is a tumor biomarker in pancreatic cancer (overexpressed in about 85% of pancreatic cancers), but also present in colorectal and lung cancer. Due to its frequency in pancreatic cancer, it is often used as a tumor biomarker. CEA is associated with liver metastasis therefore it is a sign of malignant cancer as well. | Nanobodies are monomeric, single-domain antibody fragments derived from camelids and are useful in therapies due to their small size and specific antigen binding. Nanobodies can be expressed in bacterial systems because unlike antibodies, it has no characteristic post-translational modification like glycosylation. Fused to a cargo they can easily penetrate solid tumors and have the desired effect like killing cells locally. Anti-CEA nanobody is targeting the immunglobulin-like glycoprotein CEA (carcinoembryonic antigen) which is a tumor biomarker in pancreatic cancer (overexpressed in about 85% of pancreatic cancers), but also present in colorectal and lung cancer. Due to its frequency in pancreatic cancer, it is often used as a tumor biomarker. CEA is associated with liver metastasis therefore it is a sign of malignant cancer as well. | ||
| − | + | ||
| Line 25: | Line 21: | ||
==References== | ==References== | ||
| − | |||
| − | |||
Lwin, T. M.; Turner, M. A.; Nishino, H.; Amirfakhri, S.; Hernot, S.; Hoffman, R. M.; Bouvet, M. Fluorescent Anti-CEA Nanobody for Rapid Tumor-Targeting and Imaging in Mouse Models of Pancreatic Cancer. Biomolecules '''2022''', 12 (5), 711. https://doi.org/10.3390/biom12050711. | Lwin, T. M.; Turner, M. A.; Nishino, H.; Amirfakhri, S.; Hernot, S.; Hoffman, R. M.; Bouvet, M. Fluorescent Anti-CEA Nanobody for Rapid Tumor-Targeting and Imaging in Mouse Models of Pancreatic Cancer. Biomolecules '''2022''', 12 (5), 711. https://doi.org/10.3390/biom12050711. | ||
| Line 37: | Line 31: | ||
Grunnet, M.; Sorensen, J. B. Carcinoembryonic Antigen (CEA) as Tumor Marker in Lung Cancer. Lung Cancer '''2012''', 76 (2), 138–143. https://doi.org/10.1016/j.lungcan.2011.11.012. | Grunnet, M.; Sorensen, J. B. Carcinoembryonic Antigen (CEA) as Tumor Marker in Lung Cancer. Lung Cancer '''2012''', 76 (2), 138–143. https://doi.org/10.1016/j.lungcan.2011.11.012. | ||
| − | + | Boon L., Yutong Y.; Reprogramming Synthetic Cells for Targeted Cancer Therapy '''2022'''; 11 (3), 1349-1360 | |
| + | DOI: 10.1021/acssynbio.1c00631 | ||
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display | ||
Latest revision as of 19:35, 10 October 2022
Anti-CEA Nanobody (C43)
CEA-specific (carcinoembryonic antigen) Nanobody is optimized for production in E. coli. This Nanobody has the ability to bind to the CEA antigen and thus can be used to identify cells over expressing the CEA antigen, which is common in various cancers.
Usage and Biology
Nanobodies are monomeric, single-domain antibody fragments derived from camelids and are useful in therapies due to their small size and specific antigen binding. Nanobodies can be expressed in bacterial systems because unlike antibodies, it has no characteristic post-translational modification like glycosylation. Fused to a cargo they can easily penetrate solid tumors and have the desired effect like killing cells locally. Anti-CEA nanobody is targeting the immunglobulin-like glycoprotein CEA (carcinoembryonic antigen) which is a tumor biomarker in pancreatic cancer (overexpressed in about 85% of pancreatic cancers), but also present in colorectal and lung cancer. Due to its frequency in pancreatic cancer, it is often used as a tumor biomarker. CEA is associated with liver metastasis therefore it is a sign of malignant cancer as well.
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 244
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 244
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 244
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 244
- 1000COMPATIBLE WITH RFC[1000]
References
Lwin, T. M.; Turner, M. A.; Nishino, H.; Amirfakhri, S.; Hernot, S.; Hoffman, R. M.; Bouvet, M. Fluorescent Anti-CEA Nanobody for Rapid Tumor-Targeting and Imaging in Mouse Models of Pancreatic Cancer. Biomolecules 2022, 12 (5), 711. https://doi.org/10.3390/biom12050711.
De Meyer, T.; Muyldermans, S.; Depicker, A. Nanobody-Based Products as Research and Diagnostic Tools. Trends in Biotechnology 2014, 32 (5), 263–270. https://doi.org/10.1016/j.tibtech.2014.03.001.
Turner, M. A.; Lwin, T. M.; Amirfakhri, S.; Nishino, H.; Hoffman, R. M.; Yazaki, P. J.; Bouvet, M. The Use of Fluorescent Anti-CEA Antibodies to Label, Resect and Treat Cancers: A Review. Biomolecules 2021, 11 (12), 1819. https://doi.org/10.3390/biom11121819.
Lee, J. H.; Lee, S.-W. The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches. Gastroenterology Research and Practice 2017, 2017, 1–11. https://doi.org/10.1155/2017/7521987.
Grunnet, M.; Sorensen, J. B. Carcinoembryonic Antigen (CEA) as Tumor Marker in Lung Cancer. Lung Cancer 2012, 76 (2), 138–143. https://doi.org/10.1016/j.lungcan.2011.11.012.
Boon L., Yutong Y.; Reprogramming Synthetic Cells for Targeted Cancer Therapy 2022; 11 (3), 1349-1360 DOI: 10.1021/acssynbio.1c00631